Payment overview · 2025
General Payments
$324.69
18 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher Warren Stumbo, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAZARD, KY · NPI 1962962548
Verified facts
What the public records show
CMS Open Payments records show Christopher Warren Stumbo, MD received $324.69 in general payments during 2025 across 18 reported records.
VERTEX PHARMACEUTICALS INCORPORATED accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Trelegy Ellipta, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $42.49 | 13.1% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.45 | 13.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.72 | 12.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.00 | 10.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.56 | 8.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.65 | 6.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.34 | 6.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.92 | 5.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.91 | 5.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.42 | 5.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.78 | 4.5% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $14.28 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.17 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $324.69 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $42.49 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $42.45 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.56 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.56 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 494 | 129 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 374 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 358 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 70 |
| Lisinopril | Lisinopril | 281 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 54 |
| Clonazepam | Clonazepam | 230 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 68 |
| Tramadol Hcl | Tramadol Hcl | 177 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 64 |
| Metformin Hcl | Metformin Hcl | 154 | 45 |
| Furosemide | Furosemide | 132 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 125 | 31 |
| Omeprazole | Omeprazole | 123 | 36 |
| Losartan Potassium | Losartan Potassium | 119 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 36 |
| Trazodone Hcl | Trazodone Hcl | 107 | 27 |
| Potassium Chloride | Potassium Chloride | 101 | 40 |
| Buspirone Hcl | Buspirone Hcl | 99 | 29 |
| Eliquis | Apixaban | 99 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 98 | 29 |
| Bumetanide | Bumetanide | 96 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 20 |
| Prednisone | Prednisone | 85 | 71 |
| Pregabalin | Pregabalin | 79 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 18 |
| Simvastatin | Simvastatin | 75 | 24 |
| Diazepam | Diazepam | 71 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 65 |
| Allopurinol | Allopurinol | 67 | 24 |
| Carvedilol | Carvedilol | 66 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | suppressed |
| Alprazolam | Alprazolam | 60 | 18 |
| Donepezil Hcl | Donepezil Hcl | 59 | 13 |
| Famotidine | Famotidine | 58 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 24 |
| Farxiga | Dapagliflozin Propanediol | 55 | 17 |
| Glipizide | Glipizide | 53 | 18 |
| Meloxicam | Meloxicam | 53 | 16 |
| Entresto | Sacubitril/Valsartan | 52 | 15 |
| Clindamycin Hcl | Clindamycin Hcl | 50 | 44 |
| Cilostazol | Cilostazol | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 11 |
| Sertraline Hcl | Sertraline Hcl | 47 | 16 |
| Bupropion Xl | Bupropion Hcl | 45 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 43 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 28 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 38 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Sucralfate | Sucralfate | 37 | 13 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Ozempic | Semaglutide | 32 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 21 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 16 |
| Azithromycin | Azithromycin | 24 | 23 |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Nystop | Nystatin | 22 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Megestrol Acetate | Megestrol Acetate | 21 | 11 |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 13 |
| Primidone | Primidone | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $324.69 · 18 records | VERTEX PHARMACEUTICALS INCORPORATED | AIRSUPRA, CAPLYTA, ELIQUIS, GIMOTI, JARDIANCE, JOURNAVX, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, PYRUKYND, REPATHA, TRELEGY ELLIPTA, VERQUVO, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error